Leukemia Research
Volume 24, Issue 7 , Pages 601-610 , July 2000

Clonal response of K562 leukemic cells to exogenous p21WAF1

  • Richard A Steinman

      Affiliations

    • Department of Medicine, University of Pittsburgh School of Medicine, 211 Lothrop Street, E1052 Biomedical Science Tower, Pittsburgh, PA 15213, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-412-6244627; fax: +1-412-6247794
    • ,
  • Beatrice Yaroslavskiy

      Affiliations

    • Department of Medicine, University of Pittsburgh School of Medicine, 211 Lothrop Street, E1052 Biomedical Science Tower, Pittsburgh, PA 15213, USA
    • ,
  • Sandra S Kaplan

      Affiliations

    • Department of Pathology, University of Pittsburgh School of Medicine, 211 Lothrop Street, E1052 Biomedical Science Tower, Pittsburgh, PA 15213, USA
    • ,
  • Julie P Goff

      Affiliations

    • Department of Radiation Oncology, University of Pittsburgh School of Medicine, 211 Lothrop Street, E1052 Biomedical Science Tower, Pittsburgh, PA 15213, USA
    • ,
  • Donna S Shields

      Affiliations

    • Department of Radiation Oncology, University of Pittsburgh School of Medicine, 211 Lothrop Street, E1052 Biomedical Science Tower, Pittsburgh, PA 15213, USA

Received 18 December 1999 ,Accepted 21 January 2000.

References 

  1. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al.  WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825
  2. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21Cdk-interacting protein Cip1 is a potent inhibitor of G1-cyclin-dependent kinases. Cell. 1993;75:805–816
  3. Zhang HS, Postigo AA, Dean DC. Active transcriptional repression by the Rb–E2F complex mediates G1 arrest triggered by p16INK4a, TGFβ, and contact inhibition. Cell. 1999;97:53–61
  4. Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA, El-Houseini ME. Induction of p21(WAF1/CIP1) during differentiation. Oncogene. 1994;9:3389–3396
  5. Halevy O, novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, et al.  Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science. 1995;267:1018–1022
  6. Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science. 1995;267:1022–1024
  7. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak K, Lee M-H, et al.  Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570–573
  8. Michieli P, Marcio C, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 1994;54:3391–3395
  9. Steinman RA, Huang J-P, Yaroslavskiy B, Goff J, Ball ED, Nguyen A. Regulation of p21 (Waf1) during myelopoiesis. Blood. 1998;91:4531–4542
  10. Yaroslavskiy B, Watkins S, Donnenberg AD, Patton TJ, Steinman RA. Subcellular and cell-cycle expression profiles of CDK-inhibitors in normal differentiating myeloid cells. Blood. 1999;93:2907–2917
  11. Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Set PK, et al.  Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science. 1998;280:1069–1072
  12. Braun SE, Mantel C, Rosenthal M, Cooper S, Liu L, Robertson KA, et al.  A positive effect of p21cip1/waf1 in the colony formation from murine myeloid progenitor cells as assessed by retroviral-mediated gene transfer. Blood Cells Mol. Dis. 1998;24:138–148
  13. Suzuki A, Tsutomi Y, Miura M, Akahane K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene. 1999;18:1239–1244
  14. Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, et al.  Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999;18:1223–1234
  15. Shim J, Lee H, Park J, Kim H, Choi EJ. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature. 1996;381:804–807
  16. Steinman RA. p21WAF1 inhibits leukemic apoptosis and prevents downmodulation of the apoptotic inhibitor protein c-IAP1 1999 (submitted).
  17. Zhang W, Kornblau SM, Kobayashi T, Gambel A, Claxton D, Deisseroth AB. High levels of constitutive WAF1/CIP1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res. 1995;1:1051
  18. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the cdk inhibitor p21 by vitamin d-3 leads to the induced differentiation of the myelomonocytic cell line u937. Genes Dev. 1996;10:142–153
  19. Matsumura I, Ishikawa J, Nakajima K, Oritani K, Tomiyama Y, Miyagawa JI, et al.  Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/CIP1) by Stat5. Mol. Cell. Biol. 1997;17:2933–2943
  20. Casini T, Pelicci PG. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene. 1999;18:3235–3243
  21. Erhardt JA, Pittman RN. Ectopic p21(WAF1) expression induces differentiation-specific cell cycle changes in PC12 cells characteristic of nerve growth factor treatment. J. Biol. Chem. 1998;273:23517–23523
  22. Erhardt JA, Pittman RN. p21WAF1 induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells. Oncogene. 1998;16:443–451
  23. Harvat BL, Wang A, Seth P, Jetten AM. Up-regulation of p27Kip1, p21WAF1/Cip1 and p16Ink4a is associated with, but not sufficient for, induction of squamous differentiation. J. Cell. Sci. 1998;111:1185–1196
  24. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45:321–334
  25. Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS. A multipotential leukemia cell line (K-562) of human origin. Proc. Soc. Exp. Biol. Med. 1981;166:546–550
  26. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, et al.  Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int. J. Cancer. 1976;18:421–431
  27. Croce CM, Huebner K, Isobe M, Fainstain E, Lifshitz B, Shtivelman E, et al.  Mapping of four distinct BCR-related loci to chromosome region 22q11: order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints. Proc. Natl. Acad. Sci. USA. 1987;84:7174–7178
  28. Rowley PT, Ohlsson-Wilhelm BM. Demonstration of commitment by K562 human erythroleukemia cells. Prog. Clin. Biol. Res. 1985;191:217–231
  29. Leary JF, Ohlsson-Wilhelm BM, Giuliano R, LaBella S, Farley B, Rowley PT. Multipotent human hematopoietic cell line K562: lineage-specific constitutive and inducible antigens. Leuk. Res. 1987;11:807–815
  30. Feinstein E, Gale RP, Reed J, Canaani E. Expression of the normal p53 gene induces differentiation of K562. Oncogene. 1992;7:1853–1857
  31. Soddu S, Blandino G, Scardigli R, Coen S, Marchetti A, Rizzo MG, et al.  Interference with p53 protein inhibits hematopoietic and muscle differentiation. J. Cell Biol. 1996;134:193–204
  32. Sheikh MS, Chen YQ, Smith ML, Fornace AJ. Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. Oncogene. 1997;14:1875–1882
  33. Cheng T, Wang Y, Dai W. Transcription factor egr-1 is involved in phorbol12-myristate 13-acetate-induced megakaryocytic differentiation of K562 cells. J. Biol. Chem. 1994;269:30848–30853
  34. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene. 1990;5:1095–1097
  35. Giannola DM, Shlomchik WD, Emerson SG. Regulation of homeobox gene 2f(b4) transcription in the myeloleukemic cell line K562. Blood. 1997;10:304a
  36. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 1991;266:17747–17753
  37. Johnson WE, Jones NA, Rowlands DC, Williams A, Guest SS, Brown G. Down-regulation but not phosphorylation of stathmin is associated with induction of HL60 cell growth arrest and differentiation by physiological agents. FEBS Lett. 1995;364:309–313
  38. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res. 1996;56:1445–1450
  39. Ahn J, Murphy M, Kratowicz S, Wang A, Levine AJ, George DL. Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. Oncogene. 1999;18:5954–5958
  40. Trepel M, Scheding S, Groscurth P, Horny H-P, Malipiero U, Brugger W, et al.  A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia. 1997;11:1842–1849
  41. Delavaine L, La Thangue NB. Control of E2F activity by p21Waf1/Cip1. Oncogene. 1999;18:5381–5392
  42. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J. 1996;15:5290–5298
  43. Schubart UK, Xu J, Fan W, Cheng G, Goldstein H, Alpini G, et al.  Widespread differentiation stage-specific expression of the gene encoding phosphoprotein p19 (metablastin) in mammalian cells. Differentiation. 1992;51:21–32
  44. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 1991;266:17747–17753
  45. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res. 1996;56:1445–1450
  46. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo (see comments). Nat. Med. 1995;1:1052–1056
  47. Thorsteinsdottir U, Sauvageau G, Humphries RK. Hox homeobox genes as regulators of normal and leukemic hematopoiesis. Hematol. Oncol. Clin. North Am. 1997;11:1221–1237

PII: S0145-2126(00)00020-5

Leukemia Research
Volume 24, Issue 7 , Pages 601-610 , July 2000

Article Tools

* Image Usage & Resolution